Quest Diagnostics | 8-K: Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
Quest Diagnostics | DEFA14A: Others
Quest Diagnostics | DEF 14A: Definitive information statements
Quest Diagnostics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Quest Diagnostics | 8-K: Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
Quest Diagnostics | 8-K: Quest Diagnostics Prices $750 Million of Senior Notes
Quest Diagnostics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Quest Diagnostics | 8-K: Quest Diagnostics Reports Third Quarter 2023 Financial Results and Updates Guidance for Full Year 2023
Quest Diagnostics | 8-K: Dr. Gail R. Wilensky announces that she is relinquishing her reelection to the Board of Directors and is stepping down from the Board upon the expiration of her current term as a director
Quest Diagnostics | 8-K: Quest Diagnostics Reports Second Quarter 2023 Financial Results and Updates Guidance for Full Year 2023
Quest Diagnostics | 8-K: Voting results of the 2023 Annual General Meeting of Shareholders
Quest Diagnostics | 8-K: Quest Diagnostics Reports First Quarter 2023 Financial Results
Quest Diagnostics | DEFA14A: Others
Quest Diagnostics | DEF 14A: Definitive proxy statements
Quest Diagnostics | 8-K: Quest Diagnostics to Discuss Strategic Priorities to Drive Growth and Create Shareholder Value at 2023 Investor Day
Quest Diagnostics | 8-K: Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board
Quest Diagnostics | 8-K: QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2023
Quest Diagnostics | 8-K: Current report
Quest Diagnostics | 8-K: Current report
Quest Diagnostics | 8-K: Current report
No Data